Phase 1 immuno-oncology biotech developing CD47 checkpoint inhibitors.
Industry: Health Care
First Day Return: +57.9%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 06/26/2020 |
Offer Price | $19.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 8.5 |
Deal Size ($mm) | $162 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 07/16/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $162 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Burlingame, CA, United States |
Founded | 2015 |
Employees at IPO | 24 |
Website alxoncology.com |